home / stock / trvn / trvn news


TRVN News and Press, Trevena Inc. From 11/14/23

Stock Information

Company Name: Trevena Inc.
Stock Symbol: TRVN
Market: NASDAQ
Website: trevena.com

Menu

TRVN TRVN Quote TRVN Short TRVN News TRVN Articles TRVN Message Board
Get TRVN Alerts

News, Short Squeeze, Breakout and More Instantly...

TRVN - Expected US Company Earnings on Tuesday, November 14th, 2023

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

TRVN - Trevena Q3 Earnings Preview

2023-11-13 10:15:38 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena Q3 Earnings Preview

TRVN - Notable earnings before Tuesday's open

2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...

TRVN - Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial resul...

TRVN - Expected US Company Earnings on Wednesday, November 8th, 2023

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

TRVN - Expected earnings - Trevena Inc.

Trevena Inc. (TRVN) is expected to report $-0.47 for Q3 2023

TRVN - Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023...

TRVN - Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates VOLITION data to be presented at the American Society of Anesthe...

TRVN - Genfit, CymaBay, Palisade among healthcare movers

2023-09-07 10:00:14 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

TRVN - BHP, TIGR and TRVN among pre-market losers

2023-09-07 08:43:42 ET Losers: NeuBase Therapeutics ( NBSE ) -25% . Sportsman's Warehouse Holdings ( SPWH ) -23% after Q2 earning release . Palisade Bio ( PALI ) -19% . Yext ( YEXT ) -16% after Q2 earning release . Verint Systems...

Previous 10 Next 10